期刊
TRANSPLANTATION
卷 78, 期 5, 页码 755-757出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.TP.0000129813.54517.25
关键词
hydroxyurea; Epstein-Barr virus; lymphoproliferative disease; cytotoxic T-cell lymphocytes; hematopoietic stem-cell transplantation
资金
- NCI NIH HHS [R01 CA 61834, P01 CA094237] Funding Source: Medline
- NCRR NIH HHS [RR 00188] Funding Source: Medline
Epstein-Barr virus (EBV) lymphoproliferative disease (LPD) is a potentially fatal complication that may follow allogeneic hematopoietic stem-cell transplantation (HSCT). In this article, the authors report a 2-year-old girl with Hurler's syndrome who developed multiple central nervous system (CNS) EBV LPD lesions 1 year after unrelated donor HSCT. Before this CNS occurrence, the patient had a complete response to rituximab treatment for EBV LPD of the spleen and lymph nodes; however, treatment of the CNS disease with rituximab proved ineffective. Because of reported favorable response of primary CNS EBV LPD in two human immunodeficiency virus-positive patients, the authors treated this patient with low-dose oral hydroxyurea. The patient improved clinically, with a decrease in size of multiple EBV LPD brain lesions. Subsequently, the patient received EBV-specific cytotoxic T-cell lymphocytes and remains well. The benefit and limited toxicity of hydroxyurea therapy merit its further consideration as treatment for EBV LPD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据